The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Drugging the ‘undruggable’ cancer targets
Open accessAbstract
The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Transcription factors have remained challenging drug targets due to the absence of druggable active sites (14).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Self-citationPeptide therapeutics: current status and future directions
Fosgerau, K., & Hoffmann, T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.003 · Cited by 3,160
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Antonarakis, E. S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J. C., Chen, Y., Mohammad, T. A., Chen, Y., Fedor, H. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315815 · Cited by 2,710
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citationDrugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., et al. (2013) · Nature · doi:10.1038/nature12138 · Cited by 1,683
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 949
GAB functions as a bioenergetic and signalling gatekeeper to control T cell inflammation
Kang, S., Liu, L., Wang, T., Cannon, M. V., Lin, P., Fan, T. W. ‐., Scott, D. A., Wu, H.-J. J., Lane, A. N., & Wang, R. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00638-1 · Cited by 48
Yang, Y., Ding, L., Zhou, Q., Li, F., Cao, Y.-H., Sun, J., Zhou, X., & Liu, A. (2020) · Cancer Cell International · doi:10.1186/s12935-019-1072-y · Cited by 49
Grand, M. L., Mukha, A., Püschel, J., Valli, E., Kamili, A., Vittorio, O., Dubrovska, A., & Kavallaris, M. (2020) · Theranostics · doi:10.7150/thno.42602 · Cited by 48
Dutta, K., Kanjilal, P., Das, R., & Thayumanavan, S. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202010412 · Cited by 50
FIREWORKS: a bottom-up approach to integrative coessentiality network analysis
Amici, D. R., Jackson, J. M., Truica, M. I., Smith, R. S., Abdulkadir, S. A., & Mendillo, M. L. (2020) · Life Science Alliance · doi:10.26508/lsa.202000882 · Cited by 47
PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery
Ermondi, G., Jiménez, D. G., & Caron, G. (2021) · Molecules · doi:10.3390/molecules26030672 · Cited by 48
Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy
Sun, X., Li, Y., Sears, R. C., & Dai, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679445 · Cited by 55
Wang, Q., Yang, Y., Liu, D., Ji, Y. R., Gao, X., Yin, J., & Yao, W. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01190 · Cited by 47
ATAD2 in cancer: a pharmacologically challenging but tractable target
Hussain, M., Zhou, Y., Song, Y., Hameed, H. M. A., Jiang, H., Tu, Y., & Zhang, J. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1406921 · Cited by 48
Qin, H., Jiang, Y., Zhang, J., Deng, C., & Zhong, Z. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00691 · Cited by 49
Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes
Doherty, L. M., Mills, C. E., Boswell, S. A., Liu, X., Hoyt, C. T., Gyori, B. M., Buhrlage, S. J., & Sorger, P. K. (2022) · eLife · doi:10.7554/elife.72879 · Cited by 50
Tilting MYC toward cancer cell death
Harrington, C. T., Sotillo, E., Dang, C. V., & Thomas‐Tikhonenko, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.08.002 · Cited by 48
Self-citationDanesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
Li, X., Liu, Q., Xie, X., Peng, C., Pang, Q., Liu, B., & Han, B. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01712 · Cited by 46
N-of-1 Trials in Cancer Drug Development
Gouda, M. A., Buschhorn, L., Schneeweiß, A., Wahida, A., & Subbiah, V. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1377 · Cited by 47
Zheng, C., Wang, C., Sun, D., Wang, H., Li, B., Liu, G., Liu, Z., Zhang, L., & Xu, P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115393 · Cited by 47
RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Saeed, O. A. M., Antonio Lopez-beltran, B., Fisher, K. W., Scarpelli, M., Montironi, R., Cimadamore, A., Massari, F., Santoni, M., & Liang Cheng, C. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205471 · Cited by 47
Bioactive cell penetrating peptides and proteins in cancer: a bright future ahead
Jauset, T., & Beaulieu, M.-È. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.03.014 · Cited by 45
Sena, L. A., Kumar, R., Sanin, D. E., Thompson, E. A., Rosen, D. M., Dalrymple, S. L., Antony, L., Yang, Y., Gomes‐Alexandre, C., Hicks, J. L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162396 · Cited by 46
Epigenetic enzyme mutations as mediators of anti-cancer drug resistance
Chen, S., Zhao, Y., Liu, S., Zhang, J., Assaraf, Y. G., Cui, W., & Wang, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100821 · Cited by 47
Delivering on the promise of recombinant silk-inspired proteins for drug delivery
González‐Obeso, C., Hartzell, E. J., Scheel, R. A., & Kaplan, D. L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114622 · Cited by 44
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 51
Tackling Undruggable Targets with Designer Peptidomimetics and Synthetic Biologics
Swenson, C., Mandava, G., Thomas, D. M., & Moellering, R. E. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00423 · Cited by 55
Hong, S.-K., Lee, H., Kwon, O., Song, N., Lee, H.-J., Kang, S., Kim, J., Kim, S., Kim, W., & Cha, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0924-8 · Cited by 45
Zhang, Y., Zhou, L., Bandyopadhyay, D., Sharma, K., Allen, A. J., Kmieciak, M., & Grant, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3788 · Cited by 45
Stitou, M., Toufik, H., Bouachrıne, M., & Lamchouri, F. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1707122 · Cited by 44
Zhao, Y., Wang, Y., Chen, W., Bai, S., Wang, P., Zheng, M., Yang, Y., Cheng, B., & Luan, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02390-0 · Cited by 45
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45
Proactive and reactive roles of TGF-β in cancer
Kuburich, N. A., Sabapathy, T., Demestichas, B. R., Maddela, J. J., den Hollander, P., & Mani, S. A. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.08.002 · Cited by 43
Depauw, S., Lambert, M., Jambon, S., Paul, A., Peixoto, P., Nhili, R., Marongiu, L., Figeac, M., Dassi, C., Paul-Constant, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01448 · Cited by 45
PH-domain-binding inhibitors of nucleotide exchange factor BRAG2 disrupt Arf GTPase signaling
Nawrotek, A., Benabdi, S., Niyomchon, S., Kryszke, M.-H., Ginestier, C., Cañeque, T., Tepshi, L., Mariani, A., St.Onge, R. P., Giaever, G. N., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0228-3 · Cited by 45
KRAS(G12C)–AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations
Pantsar, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-68950-y · Cited by 45
Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
Wołowiec, Ł., Osiak, J., Wołowiec, A., Wijata, A., Grześk, E., Kozakiewicz, M., Banach, J., Nowaczyk, A., Nowaczyk, J., & Grześk, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020323 · Cited by 43
Uniyal, P., Kashyap, V. K., Behl, T., Parashar, D., & Rawat, R. (2025) · Cancers · doi:10.3390/cancers17050785 · Cited by 48
Emdal, K. B., Pedersen, A.-K., Bekker‐Jensen, D. B., Lundby, A., Claeys, S., Preter, K. D., Speleman, F., Francavilla, C., & Olsen, J. V. (2018) · Science Signaling · doi:10.1126/scisignal.aap9752 · Cited by 40
The Nanosystems Involved in Treating Lung Cancer
Crintea, A., Duţu, A., Samaşcă, G., Florian, I. A., Lupan, I., & Craciun, A. M. (2021) · Life · doi:10.3390/life11070682 · Cited by 43
The past, present, and future of chemotherapy with a focus on individualization of drug dosing
DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 42
Emerging Pharmacotherapeutic Strategies to Overcome Undruggable Proteins in Cancer
Lu, Y., Yang, Y., Zhu, G., Zeng, H., Fan, Y., Guo, F., Xu, D., Wang, B., Chen, D., & Ge, G. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83026 · Cited by 42
Luginbuehl, V., Meier, N., Kovar, K., & Rohrer, J. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.02.005 · Cited by 40
Zeng, L., Nikolaev, A. Y., Xing, C., Manna, D. L. D., & Yang, E. S.-H. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0946 · Cited by 40
Bianco, G., Goodsell, D. S., & Forli, S. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.10.005 · Cited by 40
eIF4E S209 phosphorylation licenses myc- and stress-driven oncogenesis
Ruan, H., Li, X., Xu, X. M., Leibowitz, B. J., Tong, J., Chen, L., Ao, L., Xing, W., Luo, J., Yu, Y., et al. (2020) · eLife · doi:10.7554/elife.60151 · Cited by 41
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells
O’Grady, S., Crown, J. P., & Duffy, M. J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01733-9 · Cited by 41
Discovery of novel BTK PROTACs for B-Cell lymphomas
Zhao, Y., Shu, Y., Lin, J., Chen, Z., Xie, Q., Bao, Y., Lu, L., Sun, N., & Wang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113820 · Cited by 40
Strategies to target the cancer driver MYC in tumor cells
Weber, L. I., & Hartl, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1142111 · Cited by 43
Repurposing AS1411 for constructing ANM-PROTACs
Fu, X., Li, J., Chen, X., Chen, H., Wang, Z., Qiu, F., Xie, D., Huang, J., Yue, S., Cao, C., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.03.011 · Cited by 41
From Concepts to Inhibitors: A Blueprint for Targeting Protein–Protein Interactions
Hong, S. H., Nguyễn, T. T., Ongkingco, J. F., Nazzaro, A., & Arora, P. S. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00046 · Cited by 45
Wang, W., Hind, T., Lam, B. W. S., & Herr, D. R. (2019) · The FASEB Journal · doi:10.1096/fj.201801635r · Cited by 39
The genomic landscape of nonsmall cell lung carcinoma in never smokers
Boeckx, B., Shahi, R. B., Smeets, D., Brakeleer, S. D., Decoster, L., Brussel, T. V., Galdermans, D., Vercauter, P., Decoster, L., Alexander, P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32797 · Cited by 40
Degraders early developability assessment: face-to-face with molecular properties
Ermondi, G., Vallaro, M., & Caron, G. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.015 · Cited by 40
Perakis, S. O., Weber, S., Zhou, Q. X., Graf, R., Hojas, S., Riedl, J. M., Gerger, A., Dandachi, N., Balić, M., Höefler, G., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000872 · Cited by 40
MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis
Yu, X., Li, W., Deng, Q., Liu, H., Wang, X., Hu, H., Cao, Y., Xu-Monette, Z. Y., Li, L., Zhang, M., et al. (2020) · Blood · doi:10.1182/blood.2020004918 · Cited by 43
Xu, J., Gu, M., Hooi, L., Toh, T. B., Thng, D. K. H., Lim, J. J., & Chow, E. K. (2021) · Nanoscale · doi:10.1039/d1nr03502a · Cited by 42
Ruiz-Pérez, M. V., Sainero‐Alcolado, L., Oliynyk, G., Matuschek, I., Balboni, N., Ubhayasekera, S. J. K. A., Snaebjornsson, M. T., Makowski, K., Aaltonen, K. E., Bexell, D., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102128 · Cited by 39
Tang, M., O’Grady, S., Crown, J. P., & Duffy, M. J. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06673-6 · Cited by 39
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 41
Bemis, T. A., Clair, J. J. L., & Burkart, M. D. (2020) · Chemical Communications · doi:10.1039/d0cc05395c · Cited by 37
Sheppard, H. E., Dall’Agnese, A., Park, W. D., Shamim, M., Dubrulle, J., Johnson, H. L., Stossi, F., Cogswell, P. C., Sommer, J., Levy, J. B., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100188 · Cited by 40
Børretzen, A., Gravdal, K., Haukaas, S. A., Mannelqvist, M., Beisland, C., Akslen, L. A., & HALVORSEN, O. J. (2021) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.202 · Cited by 42
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 38
NetBID2 provides comprehensive hidden driver analysis
Dong, X., Ding, L., Thrasher, A., Wang, X., Liu, J., Pan, Q., Rash, J., Dhungana, Y., Yang, X., Risch, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38335-6 · Cited by 37
Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer
Lin, J., Liu, H., Wu, Y., Jin, J., Zhou, Y., Zhang, H., Nagle, D. G., Chen, H., Zhang, W., & Luan, X. (2023) · Small · doi:10.1002/smll.202207778 · Cited by 38
Degrading proteins in animals: “PROTAC”tion goes in vivo
Guo, J., Liu, J., & Wei, W. (2019) · Cell Research · doi:10.1038/s41422-019-0144-9 · Cited by 38
Martinez-Rosell, G., Lovera, S., Sands, Z. A., & Fabritiis, G. D. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01209 · Cited by 38
Fluorescence Anisotropy-Based Tethering for Discovery of Protein–Protein Interaction Stabilizers
Sijbesma, E., Somsen, B. A., Miley, G. P., de Gevel, I. A. L.-V., Brunsveld, L., Arkin, M. R., & Ottmann, C. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00646 · Cited by 38
Emerging Trends in Cancer Drug Discovery—From Drugging the “Undruggable” to Overcoming Resistance
Rudolph, J., Settleman, J., & Malek, S. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0260 · Cited by 42
Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras
Zhao, C., & Dekker, F. J. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00089 · Cited by 38
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma
Grillone, K., Riillo, C., Rocca, R., Ascrizzi, S., Spanò, V., Scionti, F., Polerà, N., Maruca, A., Barreca, M., Juli, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810222 · Cited by 37
MYC the oncogene from hell: Novel opportunities for cancer therapy
Papadimitropoulou, A., Makri, M., & Zoidis, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116194 · Cited by 40
Kwon, O., Lee, H., Kong, H., Kwon, E.-J., Park, J. E., Lee, W., Kang, S., Kim, S., Kim, W., & Cha, H. (2020) · Oncogene · doi:10.1038/s41388-020-1316-2 · Cited by 37
Modulating undruggable targets to overcome cancer therapy resistance
Passirani, C., Vessières, A., Regina, G. L., Link, W., & Silvestri, R. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100788 · Cited by 37
Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations
Tang, Y., Song, H., Wang, Z., Xiao, S., Xiang, X., Zhan, H., Wu, L., Wu, J., Xing, Y., Tan, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110622 · Cited by 37
Learning About Allosteric Drugs and Ways to Design Them
Tan, Z. W., Tee, W.-V., & Berezovsky, I. N. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167692 · Cited by 37
Copy Number Variations in Pancreatic Cancer: From Biological Significance to Clinical Utility
Oketch, D. J. A., Giulietti, M., & Piva, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010391 · Cited by 36
Wang, Y., Ma, X., Xu, E., Huang, Z. Y., Chen, Y., Zhu, K., Dong, Y., & Zhang, C. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1586 · Cited by 36
Ogasawara, D., Konrad, D. B., Tan, Z. Y., Carey, K. L., Luo, J., Won, S. J., Li, H., Carter, T. R., DeMeester, K. E., Njomen, E., et al. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.005 · Cited by 31
Jackson, M. A., Bedingfield, S. K., Yu, F. Z., Stokan, M. E., Miles, R. E., Curvino, E. J., Hoogenboezem, E. N., Bonami, R. H., Patel, S. S., Kendall, P. L., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.11.010 · Cited by 33
Alptekin, A., Ye, B., Yu, Y., Poole, C. J., van Riggelen, J., Zha, Y., & Ding, H. (2019) · Oncogene · doi:10.1038/s41388-019-0967-3 · Cited by 35
Wu, C.-S., Wu, S., Chen, H.-C., Chu, C., Tang, H. F., Liu, H., Hong, Y., Huang, C. F., Huang, G.-C., & Su, C. (2019) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2019.108227 · Cited by 35
Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review
Morshedi, K., Borran, S., Ebrahimi, M. S., khooy, M. J. M., Seyedi, Z. S., Amiri, A., Abbasi‐Kolli, M., Fallah, M., Khan, H. Z., Sahebkar, A., et al. (2021) · Phytotherapy Research · doi:10.1002/ptr.7119 · Cited by 38
Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation
Wu, M. Y., Zhang, E. W., Strickland, M. R., Mendoza, D. P., Lipkin, L., Lennerz, J. K., Gainor, J. F., Heist, R. S., & Digumarthy, S. R. (2021) · Cancers · doi:10.3390/cancers13143572 · Cited by 35
Zheng, L., Feng, Z., Tao, S., Gao, J., Lin, Y., Wei, X., Zheng, B., Huang, B. H., Zheng, Z., Zhang, X., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.652 · Cited by 34
Zhou, J., Zhang, B., Wang, H., Wang, D., Zhang, M., Zhang, M., Wang, X., Fan, S., Xu, Y., Zeng, Q., et al. (2022) · Advanced Science · doi:10.1002/advs.202201166 · Cited by 32
Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC–Driven Cancer Progression
Gao, J., Jung, M., Mayoh, C., Venkat, P., Hannan, K. M., Fletcher, J. I., Kamili, A., Gifford, A. J., Kusnadi, E. P., Pearson, R. B., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3914 · Cited by 34
Busonero, C., Leone, S., Bartoloni, S., & Acconcia, F. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.020 · Cited by 34
Targeting MYC: From understanding its biology to drug discovery
Ross, J., Miron, C. E., Plescia, J., LaPlante, P., McBride, K. M., Moitessier, N., & Möröy, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113137 · Cited by 35
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 34
Proteome‐Wide Fragment‐Based Ligand and Target Discovery
Forrest, I., & Parker, C. G. (2023) · Israel Journal of Chemistry · doi:10.1002/ijch.202200098 · Cited by 31
Membrane Permeability in a Large Macrocyclic Peptide Driven by a Saddle-Shaped Conformation
Faris, J. H., Adaligil, E., Popovych, N., Ono, S., Takahashi, M., Nguyen, H. Q., Plise, E. G., Taechalertpaisarn, J., Lee, H., Koehler, M. F. T., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c10949 · Cited by 34
Overview of host-directed antiviral targets for future research and drug development
Gu, X., Zheng, M., Gao, Y. M., Lin, S. J., Zhang, X., Chen, C., Zhu, H., Sun, W., & Zhang, Y. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.011 · Cited by 32
Allosteric inhibitors of the STAT3 signaling pathway
Qin, J., Shen, X., Zhang, J., & Jia, D. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112122 · Cited by 33
Dhanasekaran, R., Park, J., Yevtodiyenko, A., Bellovin, D. I., Adam, S. J., Rajan, A., Gabay, M., Fernando, H., Arzeno, J., Arjunan, V., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.008 · Cited by 32
Nano‐Oncologicals: A Tortoise Trail Reaching New Avenues
Dacoba, T. G., Anthiya, S., Berrecoso, G., Fernández‐Mariño, I., Fernández‐Varela, C., Crecente‐Campo, J., Teijeiro‐Osorio, D., Torres, F., & Alonso, M. J. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009860 · Cited by 34
Gharaibeh, L. F., Alshaer, W., Wehaibi, S., Buqain, R. A., Alqudah, D. A., Al-Kadash, A., Al-Azzawi, H., Awidi, A., & Bustanji, Y. K. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102733 · Cited by 33
Methods to identify protein targets of metal-based drugs
Skos, L., Borutzki, Y., Gerner, C., & Meier, S. M. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102257 · Cited by 33
Murage, N. W., Ahmed, N. M., Underwood, T., Walters, Z. S., & Breininger, S. P. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10088-0 · Cited by 32
Targeting peptide antigens using a multiallelic MHC I-binding system
Du, H., Mallik, L., Hwang, D. H., Sun, Y., Kaku, C. I., Hoces, D., Sun, S. M., Ghinnagow, R., Carro, S. D., Phan, H. A. T., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02505-8 · Cited by 33
Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment
Izreig, S., Gariepy, A., Kaymak, I., Bridges, H. R., Donayo, A. O., Bridon, G., DeCamp, L. M., Kitchen-Goosen, S. M., Avizonis, D. Z., Sheldon, R. D., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100014 · Cited by 31
Khan, A., Aljarbou, A. N., Aldebasi, Y. H., Allemeilam, K. S., Alsahly, M. A., Khan, S., Alruwetei, A. M., & Khan, M. A. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s256022 · Cited by 32
Metadata
- Authors
- Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L.
- Affiliations
- The Wistar Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Howard Hughes Medical Institute (US)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Dang, Chi V.
- Reddy, E. Premkumar
- Shokat, Kevan M.
- Soucek, Laura
- Venue
- Nature Reviews Cancer
- Published
- 2017-06-23
- Volume
- 17
- Issue
- 8
- Pages
- 502-508
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC5945194
- OpenAlex
- W2692768525
- Cited by
- 927
- References
- 57
- Citations by year
- 2026: 93 · 2025: 113 · 2024: 125 · 2023: 110 · 2022: 121 · 2021: 121 · 2020: 113 · 2019: 63 · 2018: 58 · 2017: 10
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (R01CA057341, R01CA158209, R01CA051497)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- oncogenic Ras, MYC oncogene, oncogene targeting, anticancer drug development
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Receptors, Androgen, Oncogene Proteins, Fusion, Proto-Oncogene Proteins c-myc, NF-kappa B, ras Proteins, Proto-Oncogene Proteins c-myb, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
